Deep immunophenotyping reveals circulating activated lymphocytes in individuals at risk for rheumatoid arthritis

Jun Inamo(Colorado School of Public Health), Joshua Keegan(Brigham and Women's Hospital), Alec Griffith(Brigham and Women's Hospital), Tusharkanti Ghosh(Colorado School of Public Health), Alice Horisberger(Brigham and Women's Hospital), Kaitlyn Howard(Brigham and Women's Hospital), John F. Pulford(Brigham and Women's Hospital), Ekaterina Murzin(Brigham and Women's Hospital), Brandon L. Hancock(Brigham and Women's Hospital), Salina Dominguez(Center for Rheumatology), Miranda G. Gurra(Northwestern University), Siddarth Gurajala(Broad Institute), A. Helena Jonsson(Brigham and Women's Hospital), Jennifer Seifert(Center for Rheumatology), Marie L. Feser(Center for Rheumatology), Jill M. Norris(Colorado School of Public Health), Ye Cao(Brigham and Women's Hospital), William Apruzzese(Arthritis Society), S. Louis Bridges(Hospital for Special Surgery), Vivian P. Bykerk(Hospital for Special Surgery), Susan M. Goodman(Hospital for Special Surgery), Laura T. Donlin(Hospital for Special Surgery), Gary S. Firestein(La Jolla Institute for Immunology), Joan M. Bathon(Columbia University), Laura B. Hughes(University of Alabama at Birmingham), Andrew Filer(NIHR Birmingham Biomedical Research Centre), Costantino Pitzalis(Humanitas University), Jennifer H. Anolik(University of Rochester Medical Center), Larry W. Moreland(Center for Rheumatology), Nir Hacohen(Broad Institute), Joel M. Guthridge(Oklahoma Medical Research Foundation), Judith A. James(Oklahoma Medical Research Foundation), Carla M. Cuda(Center for Rheumatology), Harris Perlman(Center for Rheumatology), Michael B. Brenner(Brigham and Women's Hospital), Soumya Raychaudhuri(Broad Institute), Jeffrey A. Sparks(Brigham and Women's Hospital), V. Michael Holers(Arthritis Society), Kevin D. Deane(Center for Rheumatology), James A. Lederer(Brigham and Women's Hospital), Deepak A. Rao(Brigham and Women's Hospital), Fan Zhang(Brigham and Women's Hospital), Fan Zhang(Colorado School of Public Health)
Journal of Clinical Investigation
March 16, 2025
Cited by 28Open Access
Full Text

Abstract

Rheumatoid arthritis (RA) is a systemic autoimmune disease currently with no universally highly effective prevention strategies. Identifying pathogenic immune phenotypes in at-risk populations prior to clinical onset is crucial to establishing effective prevention strategies. Here, we applied multimodal single-cell technologies (mass cytometry and CITE-Seq) to characterize the immunophenotypes in blood from at-risk individuals (ARIs) identified through the presence of serum antibodies against citrullinated protein antigens (ACPAs) and/or first-degree relative (FDR) status, as compared with patients with established RA and people in a healthy control group. We identified significant cell expansions in ARIs compared with controls, including CCR2+CD4+ T cells, T peripheral helper (Tph) cells, type 1 T helper cells, and CXCR5+CD8+ T cells. We also found that CD15+ classical monocytes were specifically expanded in ACPA-negative FDRs, and an activated PAX5lo naive B cell population was expanded in ACPA-positive FDRs. Further, we uncovered the molecular phenotype of the CCR2+CD4+ T cells, expressing high levels of Th17- and Th22-related signature transcripts including CCR6, IL23R, KLRB1, CD96, and IL22. Our integrated study provides a promising approach to identify targets to improve prevention strategy development for RA.


Related Papers